Personal information

Activities

Employment (3)

Universitätsklinikum Freiburg: Freiburg, Baden-Württemberg, DE

2018-09 to present | Clinical Fellow (Hematology/Oncology)/ Clinician Scientist
Employment
Source: Self-asserted source
Kristina Maas-Bauer

Stanford Medicine: Stanford, California, US

2015-09 to 2018-08 | Postdoc/ Research Fellow (Bone and Marrow Transplantation)
Employment
Source: Self-asserted source
Kristina Maas-Bauer

Universitätsklinikum Freiburg: Freiburg, Baden-Württemberg, DE

2012-10 to 2015-08 | Residency (Oncology and Hematology)
Employment
Source: Self-asserted source
Kristina Maas-Bauer

Education and qualifications (2)

Albert-Ludwigs-Universität Freiburg: Freiburg im Breisgau, Baden-Württemberg, DE

2007-10 to 2012-05 | MD (Medical School)
Education
Source: Self-asserted source
Kristina Maas-Bauer

Universität Ulm: Ulm, Baden-Württemberg, DE

2005-10 to 2007-09 (Medical School)
Education
Source: Self-asserted source
Kristina Maas-Bauer

Professional activities (2)

European Society for Blood and Marrow Transplantation: Paris, FR

2022-03-22 | Jon Van Rood Award
Distinction
Source: Self-asserted source
Kristina Maas-Bauer

American Society of Hematology: San Diego, US

2018-12 | Abstract Achievement Award
Distinction
Source: Self-asserted source
Kristina Maas-Bauer

Funding (3)

Impact of human invariant natural killer T cell sublineages on graft versus host disease

2022-08 to 2025-07 | Grant
Else-Kröner-Fresenius-Stiftung (Bad Homburg, DE)
Source: Self-asserted source
Kristina Maas-Bauer

Human invariant natural killer T cell sublineages and their impact on graft-versus-host-disease

2021-01 to present | Salary award
Albert-Ludwigs-Universität Freiburg (Freiburg, DE)
Source: Self-asserted source
Kristina Maas-Bauer

Invariant natural killer T cells protect from Graft versus host disease

2015-09 to 2018-08 | Salary award
Deutsche Krebshilfe (Bonn, DE)
Source: Self-asserted source
Kristina Maas-Bauer

Works (15)

ROCK1/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease

Nature Communications
2024-01-10 | Journal article | Author
Part of ISSN: 2041-1723
Contributors: Kristina Maas-Bauer; Anna-Verena Stell; Kai-Li Yan; Enrique de Vega; Janaki Manoja Vinnakota; Susanne Unger; Nicolas Núñez; Johana Norona; Nana Talvard-Balland; Stefanie Koßmann et al.
Source: Self-asserted source
Kristina Maas-Bauer

Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response

British Journal of Haematology
2023-10 | Journal article
Part of ISSN: 0007-1048
Part of ISSN: 1365-2141
Contributors: Petya Apostolova; Stefanie Kreutmair; Cristina Toffalori; Marco Punta; Susanne Unger; Ann‐Cathrin Burk; Claudia Wehr; Kristina Maas‐Bauer; Wolfgang Melchinger; Eileen Haring et al.
Source: Self-asserted source
Kristina Maas-Bauer

Single-cell transcriptomics reveal different maturation stages and sublineage commitment of human thymic invariant natural killer T cells

Journal of Leukocyte Biology
2023-09-23 | Journal article | Author
Part of ISSN: 1938-3673
Contributors: Kristina Maas-Bauer; Natalie Köhler; Anna-Verena Stell; Melissa Zwick; Swati Acharya; Anne Rensing-Ehl; Christoph König; Johannes Kroll; Jeanette Baker; Stefanie Koßmann et al.
Source: Self-asserted source
Kristina Maas-Bauer

Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming.

Clinical cancer research : an official journal of the American Association for Cancer Research
2021-08 | Journal article
Contributors: Simonetta F; Lohmeyer JK; Hirai T; Maas-Bauer K; Alvarez M; Wenokur AS; Baker J; Aalipour A; Ji X; Haile S et al.
Source: Self-asserted source
Kristina Maas-Bauer via Europe PubMed Central

Activation of natural killer T cells enhances the function of regulatory T-cell therapy in suppressing murine GVHD

Blood Advances
2021-06-08 | Journal article
Part of ISSN: 2473-9529
Part of ISSN: 2473-9537
Source: Self-asserted source
Kristina Maas-Bauer

Invariant Natural Killer T Cell Subsets Have Diverse Graft-Versus-Host-Disease-Preventing and Anti-Tumor Effects

Blood
2021-05-25 | Journal article
Part of ISSN: 0006-4971
Part of ISSN: 1528-0020
Source: Self-asserted source
Kristina Maas-Bauer

Ruxolitinib-ECP combination treatment for refractory severe chronic graft-versus-host disease.

Bone marrow transplantation
2020-11-17 | Journal article
Source: Self-asserted source
Kristina Maas-Bauer

Infusion of Host-Derived Unlicensed NK Cells Improves Donor Engraftment in Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation.

Frontiers in immunology
2020-01-01 | Journal article
Source: Self-asserted source
Kristina Maas-Bauer

Activation of the DR3-TL1A Axis in Donor Mice Leads to Regulatory T Cell Expansion and Activation With Reduction in Graft-Versus-Host Disease.

Frontiers in immunology
2019-07-17 | Journal article
Source: Self-asserted source
Kristina Maas-Bauer

Invariant Natural Killer T Cells As Suppressors of Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation.

Frontiers in Immunology
2017 | Journal article
Contributors: Mavers M; Maas-Bauer K; Negrin RS
Source: Self-asserted source
Kristina Maas-Bauer via Europe PubMed Central

DR3 signaling modulates the function of Foxp3+ regulatory T cells and the severity of acute graft-versus-host disease.

Blood
2016-12 | Journal article
Source: Self-asserted source
Kristina Maas-Bauer

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.

Leukemia
2015-10 | Journal article
Contributors: Zeiser R; Burchert A; Lengerke C; Verbeek M; Maas-Bauer K; Metzelder SK; Spoerl S; Ditschkowski M; Ecsedi M; Sockel K et al.
Source: Self-asserted source
Kristina Maas-Bauer via Europe PubMed Central

Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease.

Blood
2014-04-07 | Journal article
Source: Self-asserted source
Kristina Maas-Bauer
grade
Preferred source (of 2)‎

Inhibition of protein geranylgeranylation and farnesylation protects against graft-versus-host disease via effects on CD4 effector T cells.

Haematologica
2013-01 | Journal article
Contributors: Hechinger AK; Maas K; Dürr C; Leonhardt F; Prinz G; Marks R; Gerlach U; Hofmann M; Fisch P; Finke J et al.
Source: Self-asserted source
Kristina Maas-Bauer via Europe PubMed Central

Regulation of different inflammatory diseases by impacting the mevalonate pathway.

Immunology
2009-05 | Journal article
Contributors: Zeiser R; Maas K; Youssef S; Dürr C; Steinman L; Negrin RS
Source: Self-asserted source
Kristina Maas-Bauer via Europe PubMed Central

Peer review (5 reviews for 1 publication/grant)

Review activity for Annals of hematology. (5)